抗结核药物的研究进展

被引:96
作者
何国钧
肖和平
机构
[1] 上海医科大学呼吸病研究所二部,上海医科大学呼吸病研究所二部
关键词
抗结核; 氟喹诺酮类; 结核分支杆菌; 药物;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:43 / 47
页数:5
相关论文
共 4 条
[1]  
The synergistic effects of gamma interferon and clofazimine on phagocyte function: Restoration of inhibition due to a 25 kilodalton fraction fromMycobacterium tuberculosis[J] . Ruquyya B. Parak,Ahmed A. Wadee.Biotherapy . 1991 (3)
[2]  
Tuberculosis chemotherapy, the need for new antituberculosis drugs is urgent. Bates J H. American Journal of Respiratory and Critical Care Medicine . 1995
[3]  
Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-timesweekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Hong Kong Chest Service/British Medical Research Council. The American Review of Respiratory Disease . 1991
[4]  
In vitro activities of levofloxacin used alone and in combination with first and second-line antituberculous drugs against Mycobacteriun tuberculosis. Rastogi N, Goh KS, Bryskier A, et al. Antimicrobial Agents and Chemotherapy . 1996